TY - JOUR
T1 - Association of patient, provider and facility related characteristics with statin associated side effects and statin use
T2 - Insight from the Veteran's Affairs healthcare system
AU - Jia, Xiaoming
AU - Lee, Michelle T.
AU - Ramsey, David J.
AU - Mahtta, Dhruv
AU - Akeroyd, Julia M.
AU - Turchin, Alexander
AU - Navar, Ann Marie
AU - Matheny, Michael E.
AU - Gobbel, Glenn
AU - Stone, Neil J.
AU - Nambi, Vijay
AU - Ballantyne, Christie M.
AU - Petersen, Laura A.
AU - Virani, Salim S.
N1 - Funding Information:
This work was supported by a Department of Veterans Affairs Health Services Research & Development Service Investigator Initiated Grant ( IIR 16–072 ), an American Heart Association Beginning Grant-in-Aid ( 14BGIA20460366 ), the American Diabetes Association Clinical Science and Epidemiology award ( 1-14- CE-44 ), and the Houston VA Health Services Research & Development Center for Innovations grant ( CIN13-413 ).
Funding Information:
This work was supported by a Department of Veterans Affairs Health Services Research & Development Service Investigator Initiated Grant (IIR 16–072), an American Heart Association Beginning Grant-in-Aid (14BGIA20460366), the American Diabetes Association Clinical Science and Epidemiology award (1-14- CE-44), and the Houston VA Health Services Research & Development Center for Innovations grant (CIN13-413). Support for VA/CMS data provided by the Department of Veterans Affairs, VA Health Services Research and Development Service, VA Information Resource Center (Project Numbers SDR 02-237 and 98-004). The opinions expressed reflect those of the authors and not necessarily those of the Department of Veterans Affairs or the US government. Declaration of Interest: AT: equity in Brio Systems; consultant for Proteomics International; research support from Astra-Zeneca, Edwards, Eli Lilly, Novo Nordisk, and Sanofi. AMN: research support (to institution) from Amgen, Janssen, BMS, Esperion; honoraria/consulting fees from Amgen, Astra Zeneca, BI, Esperion, Janssen, Lilly, Sanofi, Novo Nordisk, Novartis, The Medicines Company, New Amsterdam, Cerner, 89Bio, Pfizer. VN: site PI for studies sponsored by Merck, Amgen: provisional patent with Roche for use of biomarkers in prediction of heart failure. CMB: grant/research support (paid to institution) from Akcea, Amgen, Esperion, Ionis, Novartis, and Regeneron; consultant for Althera, Amarin, Amgen, Arrowhead, Astra Zeneca, Corvidia, Esperion, Genentech, Gilead, Matinas BioPharma Inc, New Amsterdam, Novartis, Novo Nordisk, Pfizer, Regeneron, Sanofi-Synthelabo. SSV: honorarium from American College of Cardiology (Associate Editor for Innovations, acc.org); Steering Committee of Patient and Provider Assessment of Lipid Management (PALM registry) at the Duke Clinical Research Institute (no financial remuneration). XJ, MTL, DJR, DM, JMA, MEM, GG, NJS, LAP do not have anything to declare.
Publisher Copyright:
© 2021
PY - 2021/11/1
Y1 - 2021/11/1
N2 - Background: Statin associated side effects (SASE) are a leading cause of statin discontinuation. Objective: We evaluated patient, provider, and facility characteristics associated with SASEs and whether these characteristics impact statin utilization. Methods: Patients with atherosclerotic cardiovascular disease (ASCVD) receiving care across the Veterans Affairs healthcare system from October 1, 2014 to September 30, 2015 were included. Multivariable logistic regression analyses were performed to determine (a) factors associated with SASE and (b) factors associated with statin use in those with SASE. Results: Our cohort included 1,225,576 patients with ASCVD. Of these, 171,189 (13.7%) had at least 1 reported SASE since year 2000. The most significant odds for SASEs were observed with female sex (odds ratio [OR] 1.40, 95% confidence interval [CI] 1.36, 1.45), White race (OR 1.43, 95% CI 1.41, 1.45), hypertension (OR 1.37, 95% CI 1.33, 1.41) and ischemic heart disease (IHD: OR 1.45, 95% CI 1.43, 1.47). Lower odds were noted with care at a teaching facility (OR 0.89, 95% CI 0.88, 0.90). Factors most associated with being on a statin among patients with SASE included having diabetes (OR 1.18, 95% CI 1.15, 1.20), IHD (OR 1.39, 95% CI 1.35, 1.43) and a higher number of cardiology visits (OR 1.08, 95% CI 1.07, 1.09), while female sex was associated with lower odds (OR 0.65, 95% CI 0.61, 0.69). Conclusion: There are significant disparities in statin use by sex, ASCVD type, and comorbidities among secondary prevention patients with SASE, which represent areas for improvement in optimizing statin utilization.
AB - Background: Statin associated side effects (SASE) are a leading cause of statin discontinuation. Objective: We evaluated patient, provider, and facility characteristics associated with SASEs and whether these characteristics impact statin utilization. Methods: Patients with atherosclerotic cardiovascular disease (ASCVD) receiving care across the Veterans Affairs healthcare system from October 1, 2014 to September 30, 2015 were included. Multivariable logistic regression analyses were performed to determine (a) factors associated with SASE and (b) factors associated with statin use in those with SASE. Results: Our cohort included 1,225,576 patients with ASCVD. Of these, 171,189 (13.7%) had at least 1 reported SASE since year 2000. The most significant odds for SASEs were observed with female sex (odds ratio [OR] 1.40, 95% confidence interval [CI] 1.36, 1.45), White race (OR 1.43, 95% CI 1.41, 1.45), hypertension (OR 1.37, 95% CI 1.33, 1.41) and ischemic heart disease (IHD: OR 1.45, 95% CI 1.43, 1.47). Lower odds were noted with care at a teaching facility (OR 0.89, 95% CI 0.88, 0.90). Factors most associated with being on a statin among patients with SASE included having diabetes (OR 1.18, 95% CI 1.15, 1.20), IHD (OR 1.39, 95% CI 1.35, 1.43) and a higher number of cardiology visits (OR 1.08, 95% CI 1.07, 1.09), while female sex was associated with lower odds (OR 0.65, 95% CI 0.61, 0.69). Conclusion: There are significant disparities in statin use by sex, ASCVD type, and comorbidities among secondary prevention patients with SASE, which represent areas for improvement in optimizing statin utilization.
KW - Statin utilization
KW - Statin-associated muscle symptoms
KW - Statin-associated side effects
UR - http://www.scopus.com/inward/record.url?scp=85117383713&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85117383713&partnerID=8YFLogxK
U2 - 10.1016/j.jacl.2021.09.050
DO - 10.1016/j.jacl.2021.09.050
M3 - Article
C2 - 34666951
AN - SCOPUS:85117383713
SN - 1933-2874
VL - 15
SP - 832
EP - 839
JO - Journal of Clinical Lipidology
JF - Journal of Clinical Lipidology
IS - 6
ER -